SASharon Adams

Sharon Adams

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sharon Adams has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • P179 Multi-center study on automating holotype HLA on a Biomek 4000

    by Efi Melista, Kim McGowan, Doreen Sese, Sharon Adams, Deborah Chen, Tunde Vago, Zach Smith, Shilpa Parakh, Peter Meintjes

  • Open Access

    Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68

    by Maria Libera Ascierto, Andrea Worschech, Zhiya Yu, Sharon Adams, Jennifer Reinboth, Nanhai G Chen, Zoltan Pos, Rahul Roychoudhuri, Giovanni Di Pasquale, Davide Bedognetti, et al.

    Oncolytic viral therapy represents an alternative therapeutic strategy for the treatment of cancer. We previously described GLV-1h68, a modified Vaccinia Virus with exclusive tropism for tumor cells, and we observed a cell line-specific relationship between the ability of GLV-1h68 to replicate in vitro and its ability to colonize and eliminate tumor in vivo. In the current study we surveyed the in vitro permissivity to GLV-1h68 replication of the NCI-60 panel of cell lines. Selected cell lines were also tested for permissivity to another Vaccinia Virus and a vesicular stomatitis virus (VSV) strain. In order to identify correlates of permissity to viral infection, we measured transcriptional profiles of the cell lines prior infection. We observed highly heterogeneous permissivity to VACV infection amongst the cell lines. The heterogeneity of permissivity was independent of tissue with the exception of B cell derivation. Cell lines were also tested for permissivity to another Vaccinia Virus and a vesicular stomatitis virus (VSV) strain and a significant correlation was found suggesting a common permissive phenotype. While no clear transcriptional pattern could be identified as predictor of permissivity to infection, some associations were observed suggesting multifactorial basis permissivity to viral infection. Our findings have implications for the design of oncolytic therapies for cancer and offer insights into the nature of permissivity of tumor cells to viral infection.


  • 94-P: KIR genes in Tunisians with nasopharyngeal carcinoma

    by Marcela R. Uribe, San Dinh, Sharon Adams, Lotfi Chouchane, David Stronceck, Francesco Marincola

  • Open Access

    HLA class I and II genotype of the NCI-60 cell lines

    by Sharon Adams, Fu-Meei Robbins, Deborah Chen, Devika Wagage, Susan L Holbeck, Herbert C Morse, David Stroncek, Francesco M Marincola

    Sixty cancer cell lines have been extensively characterized and used by the National Cancer Institute's Developmental Therapeutics Program (NCI-60) since the early 90's as screening tools for anti-cancer drug development. An extensive database has been accumulated that could be used to select individual cells lines for specific experimental designs based on their global genetic and biological profile. However, information on the human leukocyte antigen (HLA) genotype of these cell lines is scant and mostly antiquated since it was derived from serological typing. We, therefore, re-typed the NCI-60 panel of cell lines by high-resolution sequence-based typing. This information may be used to: 1) identify and verify the identity of the same cell lines at various institutions; 2) check for possible contaminant cell lines in culture; 3) adopt individual cell lines for experiments in which knowledge of HLA molecule expression is relevant. Since genome-based typing does not guarantee actual surface protein expression, further characterization of relevant cell lines should be entertained to verify surface expression in experiments requiring correct antigen presentation.